ROS-reactive PMS/PC drug delivery system improves new bone formation under diabetic conditions by promoting...

Area of Science:

• Biomaterials Science
• Nanomedicine
• Orthopedics

Background:

• Diabetes mellitus leads to increased bone fragility and fracture risk due to reactive oxygen species (ROS) overproduction and oxidative stress.
• Current treatments for diabetic bone disease often fail to address the underlying oxidative stress.
• Developing targeted therapies to manage ROS is crucial for improving bone health in diabetic patients.

Purpose of the Study:

• To develop and evaluate a ROS-reactive drug delivery system (PMS/PC) for treating diabetic bone disease.
• To investigate the mechanism by which PMS/PC regulates ROS and promotes new bone formation.
• To assess the therapeutic potential of PMS/PC in vitro and in vivo models of diabetic bone conditions.

Main Methods:

• Fabrication of phenyl sulfide mesoporous silica nanoparticles (PMS) loaded with proanthocyanidin (PC).
• In vitro studies to assess osteoblastic differentiation and ROS scavenging.
• In vivo studies in diabetic models to evaluate bone formation, angiogenesis-osteogenesis coupling, and the role of nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2).

Main Results:

• The PMS/PC system demonstrated ROS-triggered release of PC, leading to dynamic ROS regulation and homeostasis.
• PMS/PC significantly promoted osteoblastic differentiation in vitro.
• In vivo, PMS/PC enhanced ossification by promoting angiogenesis-osteogenesis coupling through NOX2 downregulation, thereby suppressing ROS and vascular oxidative stress.

Conclusions:

• The ROS-reactive PMS/PC system shows therapeutic potential for diabetic bone disease by mitigating oxidative stress.
• This approach offers a promising strategy for managing excessive ROS, a key factor in various systemic diseases.
• The findings highlight the prospects of PMS/PC in treating conditions associated with oxidative stress-induced damage.